Literature DB >> 10023322

Growth stimulation of non-small cell lung cancer xenografts by granulocyte-macrophage colony-stimulating factor (GM-CSF).

Y Oshika1, M Nakamura, Y Abe, Y Fukuchi, M Yoshimura, M Itoh, Y Ohnishi, T Tokunaga, Y Fukushima, H Hatanaka, H Kijima, H Yamazaki, N Tamaoki, Y Ueyama.   

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been suggested to be involved in the carcinogenesis of some types of tumours by autocrine or paracrine mechanisms. We examined GM-CSF/GM-CSF receptor (GM-CSFR) gene expression in 20 human non-small cell lung cancer (NSCLC) xenografts. The stimulatory effects of GM-CSF were examined using GM-CSF transgenic severe combined immunodeficient (SCID) mice (GM-Tg-SCID), which produce abundant human GM-CSF. A NSCLC xenograft (LC11-JCK), expressed GM-CSFR but not GM-CSF, and showed more rapid growth in GM-Tg-SCID than non-GM-CSF transgenic SCID mice (non-Tg-SCID). GM-CSF gene expression was detected in 48 of 90 (53%) primary NSCLC human specimens and GM-CSFR gene expression was detected in 42 specimens (47%). GM-CSF expression was detected in 13 of 30 squamous cell carcinoma specimens (43%) and GM-CSFR expression was detected in 10 specimens (33%). Patients with squamous cell carcinoma coexpressing GM-CSF and GM-CSFR showed significantly poorer prognosis than those expressing neither GM-CSF nor GM-CSFR (P < 0.05, Cox-Mantel test). These results suggest that GM-CSF can have a stimulatory effect on some NSCLC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10023322     DOI: 10.1016/s0959-8049(98)00236-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer.

Authors:  Rui Li; Dominik Rüttinger; Rong Li; Lü-Sheng Si; Yi-Li Wang
Journal:  Langenbecks Arch Surg       Date:  2003-09-19       Impact factor: 3.445

2.  A versatile technique for the in vivo imaging of human tumor xenografts using near-infrared fluorochrome-conjugated macromolecule probes.

Authors:  Hiroshi Suemizu; Kenji Kawai; Yuichiro Higuchi; Haruo Hashimoto; Tomoyuki Ogura; Toshio Itoh; Erika Sasaki; Masato Nakamura
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

3.  Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.

Authors:  Fei Ji; Shunjun Fu; Zhiyong Guo; Hui Pang; Dubo Chen; Xiaoping Wang; Weiqiang Ju; Dongping Wang; Xiaoshun He; Yunpeng Hua; Baogang Peng
Journal:  Oncotarget       Date:  2016-11-01

4.  [Paraneoplastic Leukocytosis and Thrombocytosis as Prognostic Biomarkers in Non-small Cell Lung Cancer].

Authors:  Prajwal Boddu; Dana Villlines; Mebea Aklilu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-11-20

5.  Construction of a Two-Gene Immunogenomic-Related Prognostic Signature in Lung Squamous Cell Carcinoma.

Authors:  Xiaoting Zhang; Jing Xiao; Xian Fu; Guicheng Qin; Mengli Yu; Guihong Chen; Xiaofeng Li
Journal:  Front Mol Biosci       Date:  2022-04-08

6.  CSF2 Overexpression Is Associated with STAT5 Phosphorylation and Poor Prognosis in Patients with Urothelial Carcinoma.

Authors:  Yi-Ying Lee; Wen-Jeng Wu; Chun-Nung Huang; Ching-Chia Li; Wei-Ming Li; Bi-Wen Yeh; Peir-In Liang; Ting-Feng Wu; Chien-Feng Li
Journal:  J Cancer       Date:  2016-03-26       Impact factor: 4.207

7.  STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.

Authors:  Lei Wang; Quanren Wang; Mingzhao Gao; Li Fu; Yun Li; Haitian Quan; Liguang Lou
Journal:  Cancer Sci       Date:  2018-08-31       Impact factor: 6.716

8.  Myeloid-derived suppressor cells promote epithelial ovarian cancer cell stemness by inducing the CSF2/p-STAT3 signalling pathway.

Authors:  Xiaofeng Li; Jiapo Wang; Weimin Wu; Hao Gao; Na Liu; Guangxi Zhan; Li Li; Lingfei Han; Xiaoqing Guo
Journal:  FEBS J       Date:  2020-04-17       Impact factor: 5.542

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.